Treatment
CAR-T cells clinical trials
We’re tracking 534 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT07416682RecruitingEarly Phase 1
CAR-T cell therapy for high-risk plasma cell cancers
This trial tests a new immune cell therapy (CAR-T) that targets two markers on high-risk plasma cell cancers. It aims to see if this treatment is safe and helpful for people with aggressive or resistant forms of this disease.
Beijing, Beijing MunicipalityAges 18–75 - NCT06554951Recruiting
Extracellular vesicles study in CAR-T cell therapy patients
This study looks at tiny particles called extracellular vesicles in the blood of people receiving CAR-T cell therapy for certain blood cancers. It may help researchers understand how these particles affect treatment outcomes.
Bologna, BolognaAges 18–90 - NCT06802406Recruiting
Nutrition support for transplant or cell therapy patients
This study tests a program to help patients who are getting a transplant or cell therapy and have trouble getting enough food. It provides nutrition resources to improve their health during treatment.
Stanford, CaliforniaAges 8–80 - NCT06501183RecruitingPhase 1
Immune cell therapy for CDH17-positive advanced solid tumors
This trial tests a new treatment called anti-CDH17 CAR-T cells for people with advanced solid tumors that are CDH17-positive. The therapy uses your own immune cells, modified to target and destroy cancer cells, and aims to help when other treatments have stopped working.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07617285RecruitingPhase 1
CAR-T cell therapy for relapsed or refractory acute myeloid leukemia
This trial tests a new type of cell therapy called CAR-T, which uses specially engineered immune cells to target acute myeloid leukemia (AML) that hasn't responded to standard treatment. The goal is to see if this therapy can help patients whose cancer has come back or stopped responding to chemotherapy.
BeijingAges 18–70 - NCT07231081RecruitingPhase 1
TX103 CAR-T cells for advanced solid tumors
This trial tests a new treatment called TX103 CAR-T cells for people with advanced solid tumors that have a specific protein (B7-H3). The goal is to see if these modified immune cells can shrink tumors or slow their growth.
BeijingAges 18–75 - NCT06575712Recruiting
Coping skills training to manage symptoms and daily steps
This study tests a coping skills training program to help people who have had a stem cell transplant or CAR-T cell therapy for blood cancer manage fatigue, pain, and stress. It may help you feel better and be more active in daily life.
Durham, North CarolinaAges 18–99 - NCT07010523Recruiting
CAR-T cell therapy for MSLN positive advanced solid tumors
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
HangzhouAges 18–75 - NCT06996132RecruitingPhase 2
Combination treatment for aggressive B-cell lymphoma that has returned
This trial tests a new combination approach for people whose aggressive B-cell lymphoma has come back or not responded to treatment. It uses a bispecific antibody (a type of drug that helps immune cells attack cancer cells) followed by CAR-T cell therapy (reprogramming your own immune cells to find and kill cancer), sometimes with a stem cell transplant.
TianjinAges 18–65 - NCT06461624RecruitingPhase 1
GPC3 CAR-T cell therapy for advanced liver cancer
This trial tests a new type of immune cell therapy, called CAR-T cells, that are engineered to target a protein called GPC3 found on liver cancer cells. It is for people with advanced liver cancer that has not responded to previous treatments.
Hangzhou, ZhejiangAges 18–70 - NCT05620706Recruiting
GPC-3 CAR-T for advanced liver cancer
This trial tests CAR-T cell therapy (immune cells changed to target GPC-3) for advanced hepatocellular carcinoma, especially when standard treatments no longer work or you cannot tolerate them. If eligible, the goal is to shrink tumors and help you live longer with improved cancer control.
Shenzhen, GuangdongAges 40–70 - NCT07475182RecruitingEarly Phase 1
Cell therapy for advanced solid tumors with specific proteins
This trial tests a new type of cell therapy (CAR-T and targeted DC cells) for people with advanced solid tumors that have specific proteins. It aims to see if these immune cells can shrink tumors or slow their growth.
Haikou, HainanAges 18–75 - NCT05858684RecruitingEarly Phase 1
CAR-T therapy for hard-to-control lupus
This early-phase study tests a special immune therapy (CAR-T cells) made to target disease-driving immune cells in adults with lupus that has not improved despite standard treatments. It may offer a new option for people with severe, active lupus symptoms.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05354375RecruitingPhase 1
PSMA-targeted CAR-T cell therapy for resistant prostate cancer
This Phase 1 study tests whether lab-made immune cells (CAR-T) that target PSMA can treat prostate cancer that keeps growing despite hormone treatment. It may help people whose disease no longer responds to standard endocrine (hormone-blocking) therapy.
Xuzhou, JiangsuAges 18–75 - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT07244406RecruitingPhase 2
CAR-T cell therapy for relapsed B-ALL
This trial is testing a new CAR-T cell therapy (Senl_B19) for children and young adults with B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not responded to treatment. It targets a protein called CD19 on leukemia cells to help your immune system attack the cancer.
BeijingAges 3–25 - NCT07321301RecruitingPhase 2
CAR T-cell therapy for relapsed B-cell lymphoma or leukemia
This trial tests a new type of CAR T-cell therapy for people with B-cell lymphoma or leukemia that has not responded to standard treatments. The therapy uses a special delivery system to help the cells target and kill cancer cells.
Beijing, Beijing MunicipalityAges 14–85 - NCT07236203Recruiting
Study of CAR-T therapy for relapsed large B-cell lymphoma
This study looks at factors that predict how well CAR-T therapy works for large B-cell lymphoma that has come back or not responded to treatment. It aims to help doctors better identify who may benefit from this therapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07720310Enrolling by invitation
CAR-T cell therapy for hard-to-treat lupus
This trial tests a new immune cell therapy (CAR-T) for people with lupus that hasn't gotten better with standard treatments. The goal is to see if these modified cells can calm the overactive immune system and improve symptoms.
Lyasny, Minsk OblastAges 18–70 - NCT03198546RecruitingPhase 1
CAR T therapy for advanced liver cancer with GPC3
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT03198052RecruitingPhase 1
CAR-T cell therapy for cancers with specific protein targets
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
Guangzhou, GuangdongAges 18–75 - NCT03356782RecruitingPhase 1/Phase 2
CAR T cells for advanced sarcoma
This trial tests a new type of immune cell therapy (4th generation CAR T cells) designed to recognize and attack sarcoma cells. It's for people with advanced or recurrent sarcoma whose tumors have a specific marker.
Shenzhen, GuangdongAges 1–75 - NCT03356795RecruitingPhase 1/Phase 2
CAR-T cell therapy for advanced cervical cancer
This trial is testing a new type of immune therapy called CAR-T cells for cervical cancer. The treatment uses your own immune cells that are specially trained to find and attack cancer cells that have certain markers.
Shenzhen, GuangdongAges 18–70 - NCT03937544RecruitingPhase 2/Phase 3
Study of your own CAR-T cells for hard-to-treat B-ALL
This trial tests a treatment made from your own immune cells (CAR-T cells) to help control relapsed or refractory B-ALL. It is designed for people whose disease has come back or not responded to prior therapy, and who have specific brain/spinal fluid and organ health requirements.
Bandar Tun Razak, Kuala LumpurAges 13–65
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 534 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.